ArticleScientific reports2025
Ultrasound-enhanced fine-needle biopsy improves tissue yield in head and neck tumors ex vivo.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Technical Validation of a Training Workstation for Magnet-Based Ultrasound Guidance of Fine-Needle Punctures.Sensors (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Current needle biopsy techniques, i.e., fine-needle aspiration biopsy (FNAB) and core needle biopsy (CNB), are widely utilized in cancer diagnostics but have certain shortcomings. The limited yield of diagnostic cellular material and the low sensitivity to detect various types of malignancies are well-known problems with FNAB. In contrast, CNB provides a histological sample but is typically more labor-intensive to obtain. Ultrasound-enhanced FNAB (USeFNAB) represents a novel approach that utilizes an ultrasonically oscillating fine-needle tip to enhance tissue yield. This study aims to assess the feasibility of employing USeFNAB in head and neck tumors in an ex vivo setting. Parotid gland tumors (PGT; N = 10) and neck lymph nodes of patients with head and neck cancer (HNC; N = 10) were resected and biopsied using three techniques: USeFNAB, FNAB, and CNB which served as a comparative method. The samples obtained were weighed and the yield and quality of the tissue fragments were evaluated by pathologists. Immunohistochemical staining was performed to determine whether USeFNAB had any impact on the staining characteristics of the sample. The findings showed that USeFNAB, at a 0.5 W power level, produced a tissue sample (mass) that was 1.9 times higher in the PGT group, and 4.6 times higher in the HNC group compared to FNAB. The quality of the sample obtained via USeFNAB was comparable to that of FNAB. USeFNAB did not alter the immunohistochemical staining characteristics. Overall, USeFNAB appears to be a promising tool for improving the tissue yield of fine-needle biopsy and enhancing diagnostic accuracy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.